| | | | | | Préparation | Taille des prés. | PEF | PP | QP | CQ | Composition | Titulaire de l'aut. | Cat. | | | | |
|---|
|
| février 2022 - 58 Spécialités |
|
| | | IPro | IPat | | Icatibant Spirig HC 30 mg | 3 ml | DDP | DDP | N.O. | | Solution injectable en seringue prête à l'emploi: Icatibantum 30mg / 3ml | Spirig HealthCare AG | B | FB | | G |  |
| | | IPro | IPat | | Burn-X | 7 | DDP | DDP | N.O. | | Comprimés résistants au suc gastrique: Esomeprazolum 20 mg | axapharm ag | D | FB | | G | |
| | | IPro | IPat | | Burn-X | 14 | DDP | DDP | N.O. | | Comprimés résistants au suc gastrique: Esomeprazolum 20 mg | axapharm ag | D | FB | | G | |
| L | | IPro | IPat | | Etoricoxib Zentiva 30 mg | 28 | 13.99 | 31.65 | 10% | | Comprimés filmés: Etoricoxibum 30 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Etoricoxib Zentiva 60 mg | 7 | 5.55 | 15.30 | 10% | | Comprimés filmés: Etoricoxibum 60 mg | Helvepharm AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Etoricoxib Zentiva 60 mg | 28 | 22.21 | 40.60 | 10% | | Comprimés filmés: Etoricoxibum 60 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Ezetimib-Atorvastatin-
Mepha 10/10 mg | 30 | 19.83 | 38.00 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Ezetimib-Atorvastatin-
Mepha 10/10 mg | 90 | 59.50 | 81.15 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/20 mg | 30 | 19.83 | 38.00 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/20 mg | 90 | 59.50 | 81.15 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/40 mg | 30 | 19.83 | 38.00 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/40 mg | 90 | 59.50 | 81.15 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/80 mg | 30 | 19.83 | 38.00 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib-Atorvastatin-
Mepha 10/80 mg | 90 | 59.50 | 81.15 | 10% | | Comprimés filmés: 2 Principes actifs | Mepha Pharma AG | ● B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Zonisamid Sandoz 25 mg | 14 | 8.03 | 25.15 | 10% | | Capsules: Zonisamidum 25 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Zonisamid Sandoz 50 mg | 56 | 43.70 | 63.95 | 10% | | Capsules: Zonisamidum 50 mg | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Zonisamid Sandoz 100 mg | 56 | 70.22 | 92.80 | 10% | | Capsules: Zonisamidum 100 mg | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Zonisamid Sandoz 100 mg | 98 | 120.98 | 148.00 | 10% | | Capsules: Zonisamidum 100 mg | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Ezetimib Atorvastatin
Sandoz 10 mg / 10 mg | 30 | 20.08 | 38.25 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Ezetimib Atorvastatin
Sandoz 10 mg / 10 mg | 90 | 60.24 | 81.90 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 20 mg | 30 | 20.08 | 38.25 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 20 mg | 90 | 60.24 | 81.90 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 40 mg | 30 | 20.08 | 38.25 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 40 mg | 90 | 60.24 | 81.90 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 80 mg | 30 | 20.08 | 38.25 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | | | Ezetimib Atorvastatin
Sandoz 10 mg / 80 mg | 90 | 60.24 | 81.90 | 10% | | Filmtablette: 2 Principes actifs | Sandoz
Pharmaceuticals AG | ● B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Sapropterin Dipharma 100 mg | 30 | 851.18 | 940.80 | 10% | | compressa dispersibile: Sapropterini Dihydrochloridum 100 mg | Dipharma SA | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Sapropterin Dipharma 100 mg | 120 | 2791.88 | 3052.75 | 10% | | compressa dispersibile: Sapropterini Dihydrochloridum 100 mg | Dipharma SA | B / LS / SG | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | | 66.50 | 88.75 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | | 133.01 | 161.05 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | | 266.02 | 305.75 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | | 532.04 | 595.05 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 10 | 665.05 | 739.70 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 10 | 1330.10 | 1463.00 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 10 | 2660.20 | 2909.55 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 10 | 5320.40 | 5766.55 | 10% | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Adtralza 150mg/ml | 4 | 1016.07 | 1121.45 | 10% | | Solution injectable en seringue prête à l'emploi: Tralokinumabum 150 mg/ml | LEO Pharmaceutical
Products Sarath Ltd. | B / LS | FB | | G | |
| L | | IPro | | | Jemperli 500 mg/10 ml | | 4928.97 | 5364.90 | 10% | | Concentré pour perfusion: Dostarlimabum 500mg / 10ml | GlaxoSmithKline AG | A / LS | FB | | G | |
| L | | IPro | IPat | | Klisyri | 5 | 66.43 | 88.65 | 10% | | Onguent: Tirbanibulinum 10 mg | Almirall AG | A / LS | FB | | G | |
| L | | IPro | IPat | | Brukinsa 80 mg | 120 | 4486.72 | 4896.00 | 10% | | Capsules: Zanubrutinibum 80 mg | BeiGene Switzerland
GmbH | A / LS | FB | | G | |
| L | | IPro | IPat | | Lundeos | 4 | 4.28 | 13.90 | 10% | | Capsules molles: Cholecalciferolum 20000 UI | Labatec Pharma SA | B / LS | FB | | G | |
| L | | IPro | IPat | | Cosentyx UnoReady 300 mg / 2 ml | | 1074.57 | 1185.10 | 10% | | Injektionslösung im Fertigpen: Secukinumabum 300mg / 2ml | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 20 | DDP | DDP | N.O. | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B | FB | | G | |
| | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 20 | DDP | DDP | N.O. | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B | FB | | G | |
| | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 20 | DDP | DDP | N.O. | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B | FB | | G | |
| | | IPro | IPat | V/S | Cutaquig 165 mg/ml | 20 | DDP | DDP | N.O. | | Solution injectable: Immunoglobulinum Humanum Normale 165 mg/ml | Octapharma AG | B | FB | | G | |
| | | IPro | IPat | | Mometason Viatris 50 μg | | DDP | DDP | N.O. | | | Leman SKL SA | B | FB | | G | |
| | | IPro | IPat | | Lundeos | 2 x 4 | DDP | DDP | N.O. | | Capsules molles: Cholecalciferolum 20000 UI | Labatec Pharma SA | B | FB | | G | |
| | | IPro | IPat | | Lecigon | 7 x 47 ml | DDP | DDP | N.O. | | Gel à l'application intestinale: 3 Principes actifs | Spirig HealthCare AG | B | FB | | G | |
| | | IPro | IPat | | Wegovy FixDose 0.25 mg | 4 | DDP | DDP | N.O. | | Injektionslösung im Fertigpen: Semaglutidum | Novo Nordisk Pharma AG | B | FB | | G | |
| | | IPro | | | Wegovy FixDose 0.5 mg | 4 | DDP | DDP | N.O. | | Injektionslösung im Fertigpen: Semaglutidum | Novo Nordisk Pharma AG | B | FB | | G | |
| | | IPro | | | Wegovy FixDose 1.0 mg | 4 | DDP | DDP | N.O. | | Injektionslösung im Fertigpen: Semaglutidum 1mg / 0.5ml | Novo Nordisk Pharma AG | B | FB | | G | |
| | | IPro | | | Wegovy FixDose 2.4 mg | 4 | DDP | DDP | N.O. | | Injektionslösung im Fertigpen: Semaglutidum 2.4mg / 0.75ml | Novo Nordisk Pharma AG | B | FB | | G | |
| | | IPro | | | Wegovy FixDose 1.7 mg | 4 | DDP | DDP | N.O. | | Injektonslösung im Fertigpen: Semaglutidum 1.7mg / 0.75ml | Novo Nordisk Pharma AG | B | FB | | G | |
| | | IPro | | | Vyxeos liposomal 44
mg/100 mg | | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion: 2 Principes actifs | MEDA Pharmaceuticals
Switzerland GmbH | A | FB | | G | |
| | | IPro | | | Vyxeos liposomal 44
mg/100 mg | 2 | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion: 2 Principes actifs | MEDA Pharmaceuticals
Switzerland GmbH | A | FB | | G | |
| | | IPro | | | Vyxeos liposomal 44
mg/100 mg | 5 | DDP | DDP | N.O. | | Pulver für ein Konzentrat zur Herstellung einer Infusionsdispersion: 2 Principes actifs | MEDA Pharmaceuticals
Switzerland GmbH | A | FB | | G | |
| | | IPro | IPat | | Rennie Gum | 20 | DDP | DDP | N.O. | | Wirkstoffhaltiger Kaugummi: Calcii Carbonas 750 mg | Bayer (Schweiz) AG | D | FB | | G | |
